A watchdog advisory panel, meeting at HMS, concluded Tuesday that a new class of powerful cholesterol-lowering drugs did not offer reasonable value to most patients given their high price tags. Jason Wasfy (Mass General) and Steven Pearson (Harvard Pilgrim Health Care) are quoted.
Trending News
Research Provides Clues to Spleen’s Role in Coronary Artery Disease
Genetic variants may drive visible changes in the spleen that contribute to heart disease
Patient Who Received Pig Kidney Becomes First To Progress to Human Kidney Transplant
Study shows xenotransplantation can serve as a bridge for patients with end-stage kidney disease
Pilots, Flight Attendants Have Greater Risk of Radiation-Related Cancer Death Than Other Professions
Findings support efforts to protect U.S. aircrews from cosmic radiation exposure